Pereira AC, Baeta IG, Costa Júnior SR, et al. Elastosis perforans serpiginosa in a patient with Down's syndrome. An Bras Dermatol 2010; 85: 691-694.
Lewis KG, Bercovitch L, Dill SW, Robinson-Bostom L. Acquired disorders of elastic tissue: part II. Decreased elastic tissue. J Am Acad Dermatol 2004; 51: 165-185.
Gregersen PA, Stausbøl-Grøn B, Ramsing M, Sommerlund M. Elastosis perforans serpiginosa in a patient with Down syndrome treated with imiquimod 5% cream. Dermatol Reports 2010; 2: e15, 42-43.
Mehta RK, Burrows NP, Payne CM, et al. Elastosis perforans serpiginosa and associated disorders. Clin Exp Dermatol 2001; 26: 521-524.
Vearrier D, Buka RL, Roberts B, et al. What is standard of care in the evaluation of elastosis perforans serpiginosa? A survey of pediatric dermatologists. Pediatr Dermatol 2006; 23: 219-224.
Lewis BK, Chern PL, Stone MS. Penicillamine-induced elastosis of the mucosal lip. J Am Acad Dermatol 2009; 60: 700-703.
Atzori L, Pinna AL, Pau M, Aste N. D-penicillamine elastosis perforans serpiginosa: description of two cases and review of the literature. Dermatol Online J 2011; 15: 3.
Kelly SC, Purcell SM. Imiquimod therapy for elastosis perforans serpiginosa. Arch Dermatol 2006; 142: 829-830.
Outland JD, Brown TS, Callen JP. Tazarotene is an effective therapy for elastosis perforans serpiginosa. Arch Dermatol 2002; 138: 169-171.
